S. Lipkowitz

Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.

Li Yang, Li Yang, J. Ohm, 2022, Pharmacology & therapeutics.

Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer.

S. Steinberg, K. Calzone, I. Kirsch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

S. Steinberg, S. Hewitt, S. Swain, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa).

E. Kohn, L. Minasian, J. Trepel, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

P. Dennis, M. Nau, S. Lipkowitz, 2001, Cancer research.

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

M. Nau, S. Lipkowitz, M. Cuello, 2001, Gynecologic oncology.

Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

M. Nau, E. Russell, S. Lipkowitz, 1999, Cancer research.

The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells.

S. Lipkowitz, S. Ettenberg, M. Keane, 1996, Cancer research.

Fas expression and function in normal and malignant breast cell lines.

E. Russell, S. Lipkowitz, S. Ettenberg, 1996, Cancer research.